• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
      • Cardiac Safety IconCardiac Solutions
        • Cardiac Solutions

          Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Arrhythmia Analysis

          Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Blood Pressure Services

          Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • ECG — On-site to DCT and Phase I-IV

          Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Phase I/TQT Cardiac Assessment

          Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Regulatory Consultation and Statistical Analysis Expertise

          Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

      • Clinical Adjudication
      • ECOA IconeCOA
        • eCOA Clinical Trials

          Make your clinical trials easier, faster, more engaging and accessible to all.

        • eCOA Live

          Enjoy flexible, fast and confidential site assessments at home.

        • eCOA Multimedia

          Enhance your ePRO data with photo and audio capture.

        • eCOA Rapid Start

          Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • eCOA Rater and Participant Training

          Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • eCOA Rescue Studies

          Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Suicidal Ideation

          Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

      • Medical ImagingMedical Imaging
        • Medical Imaging

          Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • Medical Imaging science team

          The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Image Redact AI

          Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Imaging Platform

          Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Modalities

          Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • SMART Submit

          Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

      • Precision Motion IconPrecision Motion
        • Precision Motion for Clinical Trials

          Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • Precision Motion for Research

          The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Precision Motion: Scientific Publications

          Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

      • Respiratory Solutions IconRespiratory
        • Respiratory Solutions

          Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Site-Based Spirometry (FEV1, FVC, PEF, and more.)

          Centralized, on-site pulmonary function testing for clinical trials.

        • Virtual Home Spirometry

          Remote spirometry testing for respiratory clinical trials.

        • Cough and Lung Sounds

          Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Diffusing Capacity (DLCO)

          Assess the capacity of the lungs for effective gas transfer.

      • Trial Enablement IconTrial Enablement
        • Trial Enablement

          Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Eligibility Solution

          Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Reporting & Analytics

          Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Source Document Manager

          Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
      • Biotechs
      • CROs
      • Pharmacist Icon RGBPharma
    • Study Phases
      • Safety Icon RGBPhase I
      • Clinical Trial Management System Icon RGBPhase II/III
    • Technology
      • AI Icon RGBArtificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Hybrid Trials
    • Biotechs
    • CROs
    • Pharma
    • Phase I
    • Phase II/III
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Type 2 Diabetes and Obesity
    • Respiratory Solutions
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles New opinions and trends in oncology PROs

New opinions and trends in oncology PROs

Learnings from the 2022 FDA COA in cancer trials workshop

Kelly Dumais, Ph.D. – Director, eCOA Science & consulting at Clario
Jowita Marszewska, Ph.D. – Scientific Advisor at Clario

The FDA’s Oncology Center of Excellence (OCE) conducts annual public workshops on clinical outcome assessments (COAs) in cancer clinical trials. These workshops bring top leaders (and importantly, patient advocates) together for interactive conversations that seek to answer our most critical questions related to the use of patient reported outcomes (PROs) in oncology trials and to ignite innovative thinking. This year in June, the 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop discussed the topic of using PROs in open label trials. We learned about overcoming barriers to incorporating PROs in open-label trials, and so much more.

Here are some key takeaways from this year’s workshop:

  • Patient-reported data should be the gold standard in understanding patient symptoms and experiences. Patients know their bodies best, and therefore, it is crucial to capture reports of their experiences with the drug using PROs. The importance of including PROs in clinical trials cannot be stressed enough considering the fact that ClinROs and ObsROs are subjective and prone to bias, with evidence that clinicians and caregivers underreport patient’s symptoms for adult and pediatric patients.1,2 Additionally, regulators often take a more conservative approach with the drug approval when PRO data is not available to complement clinician’s observations.
  • The risk of open-label bias should not prohibit the use of PROs in open label oncology trials. Most oncology trials use an open label trial design, leading to concern that the patient’s perception of their symptoms may be influenced by their knowledge of their treatment (i.e., open label bias). While the concern and need for further research was acknowledged, the collective opinion from the panelists, supported by recent literature3,4 (Atkinson et al., 2017; Efficace et al., 2022), is that there is little evidence or concern for open label bias in oncology trials and that their use in open label trials are valid and supported. Further, most oncology drug approvals that include PROs in the label were open label trials, supporting that this is an accepted practice by the FDA.

To me, the message was clear. For Oncology trials, you must use PROs to fully understand the patient experience and to better evaluate tolerability. PROs should be included as early as possible in your drug development program.

Kelly Dumais, Ph.D., Principal Scientific Advisor at Clario
  • PROs should be a standard practice in every cancer clinical trial, even in early phases. Omitting PROs in early stages of assessing drug’s safety, tolerability and pharmacokinetics can have serious implications: Drug dose can be toxic or poorly tolerated but still would be moved forward to another phase. In addition to clinician reported tolerability and adverse events (AEs), optimal dose finding should include evidence of patient tolerability via PROs. PROs that assess tolerability (e.g., PRO-CTCAE) provide complimentary information to provide a more comprehensive and granular evaluation and should be included in all cancer trials, starting at phase 1.
  • Communicate to sites and patients the value of PROs. Both experts and patients on the panel emphasized the value of an education and training of sites and patients. Patients participate in clinical trials for altruistic reasons and the more they know what is important and why, the more accurate and complete their reporting will be, leading to higher patient satisfaction and better compliance.

The industry is making significant strides in using PROs to bring the patient back to the forefront of clinical trials and making the patient voice heard. This year’s FDA workshop on COA in cancer clinical trials provided another successful display of what can be accomplished when bringing everyone to the table: Regulators, academia, international experts and patient advocates.

Enhance your understanding

Eager to grasp how eCOA can revolutionize oncology clinical trials? Delve into a world where technology meets transformative cancer research.

Learn more

Written by

Kelly Dumais, Ph.D.

Principal Scientific Advisor at Clario

Jowita Marszewska, Ph.D.

Scientific Advisor at Clario


References

1Basch E, Jia X, Heller G, et al. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. JNCI: Journal of the National Cancer Institute. 2009;101(23):1624-1632. doi:10.1093/jnci/djp386

2Freyer DR, Lin L, Mack JW, et al. Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials. JCO. 2022;40(15):1623-1634. doi:10.1200/JCO.21.02669

3Atkinson TM, Wagner JS, Basch E. Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials. JAMA Oncology. 2017;3(6):738-9.

4Efficace F, Cella D, Aaronson NK, Calvert M, Cottone F, Di Maio M, Perrone F, Sparano F, Gamper EM, Vignetti M, Giesinger JM. Impact of blinding on patient reported outcome differences between treatment arms in cancer randomized controlled trials. JNCI. 2022; 114(3):471-4.

Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Dr. Lauren Tueth

Precision Motion

Read
Article

Researcher spotlight: Brice Cleland

Precision Motion

Read
Article

Researcher spotlight: Josefa Domingos

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum